Thursday, July 31, 2014

Do Decision Aids Help Patients Make Difficult Choices? (CME/CE)

Do Decision Aids Help Patients Make Difficult Choices? (CME/CE)
MedPage Today Neurology

(MedPage Today) -- Decision aids designed to help patients make general healthcare choices, such as selecting a treatment location, provide some help, but condition-specific aids may provide the most useful information for patients and families.

Original Article: http://www.medpagetoday.com/PracticeManagement/Medicolegal/46974

Why New Tech Can't Please Everyone

Why New Tech Can't Please Everyone
Scientific American: Mind and Brain

Why it's nearly impossible to design new tech that will please everyone

-- Read more on ScientificAmerican.com


Original Article: http://www.scientificamerican.com/article/why-new-tech-cant-please-everyone/

Saturday, July 26, 2014

MicroRNAs as Biomarkers in Pituitary Tumors

MicroRNAs as Biomarkers in Pituitary Tumors
Neurosurgery - Current Issue

image The use of extracellular microRNAs (miRNAs) as circulating biomarkers is currently leading to relevant advances in the diagnosis and assessment of prognosis of several diseases. Specific miRNAs have also been shown to play a role in the pathophysiology of many neoplastic and non-neoplastic diseases. A number of studies have demonstrated that miRNAs show differential expression in various tumors, such as in the prostate, ovary, lung, breast, brain, and pituitary. Recent findings have built connections between miRNAs that are deregulated within the tumor and their presence in peripheral blood. MiRNAs have been shown to be stable in the blood where they are present in either free and/or uncomplexed form, as well as packed in microvesicles, exosomes, and apoptotic bodies, or bound to different proteins. Because the pituitary is a highly vascularized organ that releases hormones into the circulation, miRNAs would be useful biomarkers for the diagnosis of pituitary tumors, as well as for predicting or detecting recurrence after surgery. Here we review the biological significance of miRNAs in pituitary tumors and the potential value of circulating miRNAs as biomarkers. ABBREVIATIONS: ACTH, adrenocorticotropic hormone AGO, argonaute AKL, α-Klotho GH, growth hormone HCC, hepatocellular carcinoma HDL, high-density lipoprotein miRNA, microRNA NFA, nonfunctioning adenoma nt, nucleotide pre-miRNA, precursor micro-ribonucleic acid PRL, prolactin

Original Article: http://journals.lww.com/neurosurgery/Fulltext/2014/08000/MicroRNAs_as_Biomarkers_in_Pituitary_Tumors.22.aspx

Top-Ranked Hospitals for Cancer – U.S. News and World Report

Top-Ranked Hospitals for Cancer – U.S. News and World Report
National Comprehensive Cancer Network

U.S. News and World Report has issued its list of the 50 top-ranked cancer hospitals in the United States. This list features a number of NCCN Member Institutions, including the top five: Memorial Sloan Kettering Cancer Center The University of Texas MD Anderson Cancer Center Mayo Clinic Cancer Center Dana-Farber/Brigham and Women's Cancer Center The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins   ...

Original Article: http://health.usnews.com/best-hospitals/rankings/cancer

Wednesday, July 23, 2014

Management of patients with HER2-positive metastatic breast cancer: Is there an optimal sequence of HER2-directed approaches?

Management of patients with HER2-positive metastatic breast cancer: Is there an optimal sequence of HER2-directed approaches?
Cancer

The successful development of therapies targeting the human epidermal growth factor receptor 2 (HER2) has altered the natural progression of disease among patients with HER2-positive metastatic breast cancer. The monoclonal antibody trastuzumab was the first HER2-directed agent and it was associated with significantly improved outcomes for patients. Subsequently, other HER2-directed agents such as the monoclonal antibody pertuzumab, the tyrosine kinase receptor inhibitor lapatinib, and the immunoconjugate trastuzumab emtansine were developed to overcome resistance to trastuzumab and provide additional treatment options for patients. Recent data have demonstrated that the use of these HER2-directed agents improves outcomes. However, with the emergence of new HER2-targeted agents, the optimal sequencing of treatment remains unclear. Ongoing research is investigating new HER2 combinations, the role of sequencing, novel HER2-directed agents, and combinations with other targeted agents to overcome resistance. Cancer 2014 © 2014 American Cancer Society.



Original Article: http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002/cncr.28815

Livro Impresso: Após um Tumor Cerebral

Livros apos um tumor cerebral - 15058212 (IDPROD_15058212-ISBN_9788564855915) - 58% de Economia - Buscapé



http://www.buscape.com.br/apos-um-tumor-cerebral-15058212-idprod-15058212-isbn-9788564855915.html#precos

WFNS - 15th Interim Meeting of the World Federation of Neurosurgical Societies - SEPTEMBER 8-12 | 2015

WFNS - 15th Interim Meeting of the World Federation of Neurosurgical Societies - SEPTEMBER 8-12 | 2015


http://www.wfnsinterimrome2015.org/

Why Science Is Important

Why Science Is Important
Scientific American: Mind and Brain

Our own track record proves that steady federal funding support leads to success

-- Read more on ScientificAmerican.com


Original Article: http://www.scientificamerican.com/article/why-science-is-important/

Monday, July 21, 2014

New research: teaching the brain to reduce pain

New research: teaching the brain to reduce pain
Neurology News & Neuroscience News from Medical News Today

People can be conditioned to feel less pain when they hear a neutral sound, new research from the University of Luxembourg has found.

Original Article: http://www.medicalnewstoday.com/releases/279502.php